🔥 The Headline: A Strong Start to 2026

Sanofi kicked off 2026 with a powerful quarter, posting double-digit growth in both sales and its key profit metric. This performance signals that the company's strategy—focusing on new specialty drugs and vaccines—is firing on all cylinders.

💊 What's Driving the Growth: The Star Products

The quarter's success was powered by a few blockbuster medicines and a wave of successful new launches.

• 👑 Dupixent: The Undisputed Champion This flagship immunology drug had another monster quarter, with sales jumping 30.8% to €4.2 billion. It crossed the €4 billion mark for only the second time ever, driven by strong demand across its many approved uses, from asthma to skin diseases. 👉 Why it matters: Dupixent is the engine of Sanofi's growth, and its momentum shows no signs of slowing.

• 🚀 New Launches: A Booming Portfolio Sales from recently launched drugs soared by 49.6% to €1.2 billion. Key performers included:

  • ALTUVIIIO (hemophilia A): €325M, up 42.2%
  • Ayvakit (rare blood cancer): €177M
  • Sarclisa (multiple myeloma): €167M, up 30.1% 👉 Why it matters: This proves Sanofi can successfully bring new drugs to market, which is crucial for its future as older medicines face competition.

• 🧬 Vaccines & Other Segments The vaccines business grew a modest 2.1%, helped by the newly acquired Heplisav-B hepatitis shot. Some older medicines, like the blood thinner Lovenox (sales down 22.3%), continued to decline due to generic competition.

💰 The Financial Scorecard

Let's break down the key numbers. It's important to understand the difference between the official accounting profit (IFRS) and the "Business" profit Sanofi uses to show its core performance.

• Sales: €10.5 billion total, up 13.6% when you strip out currency swings.
• Business Profit (Business EPS): This is the metric management highlights. Earnings per share came in at €1.88, a 14.0% increase at constant exchange rates. 👉 The key difference: This measure excludes one-time costs like acquisition-related accounting and restructuring, giving a clearer view of underlying operations.
• Official Profit (IFRS EPS): This was €1.34, which actually fell by 11.8%. The drop is mainly due to large non-cash accounting charges from past acquisitions (like the amortization of drug patents), which are excluded from the "Business" view.
• Spending: R&D investment was €1.7 billion. Selling and admin costs rose 11.6%, mainly because Sanofi is now paying for its recent acquisitions of Blueprint and Dynavax.

🏗️ Key Strategic Moves

Sanofi was busy this quarter strengthening its business for the long term.

• M&A Completed: It finalized the $2.2 billion acquisition of Dynavax, adding the adult vaccine Heplisav-B to its portfolio.
• Returning Cash to Shareholders: It bought back €921 million of its own stock as part of a €1 billion programme and proposed a dividend of €4.12 per share, marking 31 consecutive years of increases.

🔬 Pipeline Update: Fuel for the Future

A company's future value lies in its drug pipeline. Sanofi reported significant progress.

• 5 Regulatory Approvals: All in its core focus area of immunology.
• Positive Trial Results:
  • Venglustat succeeded in a Phase 3 study for a rare brain condition linked to Gaucher disease.
  • Lunsekimab showed promise in Phase 2 for severe asthma.
• A Major Public Health Win: A 25-year partnership with the WHO led to a positive recommendation for acoziborole, a potential single-dose cure for sleeping sickness, paving the way for its use in Africa.

🔮 What's Next: Guidance Affirmed

Despite the strong start, Sanofi isn't changing its full-year forecast. It still expects:

• Sales to grow by a high single-digit percentage (at constant exchange rates).
• Business EPS to grow slightly faster than sales. 👉 Why it matters: This shows management's confidence that this strong Q1 isn't a fluke but the start of a sustained trend for the year.

⚖️ The Big Picture: Strengths & Risks

• 👍 Strengths: Dominant growth from Dupixent, a successful stream of new launches, a deep pipeline, and a strong commitment to shareholder returns.
• ⚠️ Risks: Reliance on a single mega-blockbuster (Dupixent), the constant pressure from generic competition on older drugs, and the high cost of acquisitions and R&D.

🧠 The Analogy

Think of Sanofi like a restaurant that has reinvented its menu. Dupixent is its wildly popular signature dish that everyone loves. It's also constantly adding exciting new dishes (the launch portfolio), which are becoming major draws. While some old classics are fading away, the new menu is packed with hits, attracting more customers than ever. The chef (management) is so confident in the new menu that they're investing in the kitchen (R&D & M&A) and giving profits back to the owners (share buybacks & dividends).

🧩 Final Takeaway

Sanofi is executing its transformation into a specialty care leader with impressive results. The quarter demonstrates powerful growth from its new product portfolio, anchored by the unstoppable Dupixent. While challenges remain, the company is hitting its strategic marks and setting a strong foundation for 2026.